Lonafarnib - Eiger Biopharmaceuticals

Drug Profile

Lonafarnib - Eiger Biopharmaceuticals

Alternative Names: EBP 994; MK-6336; Sarasar; SCH 066336; SCH 66336

Latest Information Update: 17 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Childrens Hospital Boston; Duke University; Eiger BioPharmaceuticals, Inc.; Merck & Co; National Institute of Diabetes and Digestive and Kidney Diseases; Schering-Plough; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors; Protein synthesis inhibitors; Squalene synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progeria; Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis D; Progeria
  • Discontinued Breast cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Glioma; Head and neck cancer; Leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 09 Nov 2018 Eiger Biopharmaceuticals has patent protection for lonafarnib in USA
  • 09 Nov 2018 CTP PUSH: 293802 updated FE, profile already brief reviewed
  • 22 Oct 2018 Lonafarnib receives Orphan Drug status for Progeria in USA prior to October 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top